Home  »  Company   »  Rubius Therapeutics Inc. (NASDAQ:RUBY) At $0.22: W...

Rubius Therapeutics Inc. (NASDAQ:RUBY) At $0.22: What To Do?

In last trading session, Rubius Therapeutics Inc. (NASDAQ:RUBY) saw 0.18 million shares changing hands with its beta currently measuring 2.41. Company’s recent per share price level of $0.22 trading at -$0.01 or -3.22% at ring of the bell on the day assigns it a market valuation of $20.68M. That closing price of RUBY’s stock is at a discount of -6045.45% from its 52-week high price of $13.52 and is indicating a premium of 9.09% from its 52-week low price of $0.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 3.57 million if we extend that period to 3-months.

Rubius Therapeutics Inc. (NASDAQ:RUBY) trade information

Upright in the red during last session for losing -3.22%, in the last five days RUBY remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $0.22 price level, adding 21.4% to its value on the day. Rubius Therapeutics Inc.’s shares saw a change of -97.70% in year-to-date performance and have moved -19.75% in past 5-day. Rubius Therapeutics Inc. (NASDAQ:RUBY) showed a performance of -31.25% in past 30-days. Number of shares sold short was 2.18 million shares which calculate 2.44 days to cover the short interests.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Rubius Therapeutics Inc. (RUBY) estimates and forecasts

Statistics highlight that Rubius Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -79.58% of value to its shares in past 6 months, showing an annual growth rate of 19.28% while that of industry is 4.60. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 50.80% in the current quarter and calculating 58.60% increase in the next quarter.

RUBY Dividends

Rubius Therapeutics Inc. is more likely to be releasing its next quarterly report between February 23 and February 27 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Rubius Therapeutics Inc. (NASDAQ:RUBY)’s Major holders

Insiders are in possession of 5.51% of company’s total shares while institution are holding 76.59 percent of that, with stock having share float percentage of 81.06%. Investors also watch the number of corporate investors in a company very closely, which is 76.59% institutions for Rubius Therapeutics Inc. that are currently holding shares of the company. Flagship Pioneering Inc. is the top institutional holder at RUBY for having 38.51 million shares of worth $8.57 million. And as of Sep 29, 2022, it was holding 42.61% of the company’s outstanding shares.

The second largest institutional holder is FMR, LLC, which was holding about 13.46 million shares on Sep 29, 2022. The number of shares represents firm’s hold over 14.89% of outstanding shares, having a total worth of $3.0 million.

On the other hand, Fidelity Growth Company Fund and Smallcap World Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2022, the former fund manager was holding 4.54 million shares of worth $1.01 million or 5.02% of the total outstanding shares. The later fund manager was in possession of 2.25 million shares on Jun 29, 2022, making its stake of worth around $0.5 million in the company or a holder of 2.49% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts